Log in

NYSE:AMRXAmneal Pharmaceuticals Stock Price, Forecast & News

$4.25
-0.02 (-0.47 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.14
Now: $4.25
$4.25
50-Day Range
$4.11
MA: $4.54
$5.27
52-Week Range
$2.27
Now: $4.25
$5.79
Volume779,358 shs
Average Volume1.74 million shs
Market Capitalization$1.27 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Read More
Amneal Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.75 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.10 per share
Book Value$1.24 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Employees5,500
Market Cap$1.27 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$4.25
-0.02 (-0.47 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

How has Amneal Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMRX shares have increased by 30.8% and is now trading at $4.25.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Amneal Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Amneal Pharmaceuticals
.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Amneal Pharmaceuticals
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) posted its quarterly earnings data on Thursday, August, 6th. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.10 by $0.03. The firm had revenue of $464.60 million for the quarter, compared to analysts' expectations of $454.26 million. Amneal Pharmaceuticals had a positive return on equity of 30.64% and a negative net margin of 11.16%. The firm's quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.09 EPS.
View Amneal Pharmaceuticals' earnings history
.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY20 earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of $0.45.0.60 for the period, compared to the Thomson Reuters consensus estimate of $0.56. The company issued revenue guidance of $1.875-1.975 billion, compared to the consensus revenue estimate of $1.91 billion.

What price target have analysts set for AMRX?

10 brokers have issued 12 month target prices for Amneal Pharmaceuticals' stock. Their forecasts range from $2.50 to $7.00. On average, they expect Amneal Pharmaceuticals' stock price to reach $4.56 in the next year. This suggests a possible upside of 7.4% from the stock's current price.
View analysts' price targets for Amneal Pharmaceuticals
.

Has Amneal Pharmaceuticals been receiving favorable news coverage?

News coverage about AMRX stock has been trending neutral on Saturday, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amneal Pharmaceuticals earned a coverage optimism score of 0.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Amneal Pharmaceuticals
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 7,390,000 shares, an increase of 26.8% from the June 15th total of 5,830,000 shares. Based on an average daily trading volume, of 1,730,000 shares, the days-to-cover ratio is currently 4.3 days. Approximately 7.8% of the shares of the company are short sold.
View Amneal Pharmaceuticals' Short Interest
.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.75%), Prudential Financial Inc. (0.40%), Bank of New York Mellon Corp (0.35%), LSV Asset Management (0.31%), Assenagon Asset Management S.A. (0.22%) and Bank of America Corp DE (0.14%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah, Paul Bisaro, Paul M Meister, Peter R Terreri, Pradeep Bhadauria and Ted C Nark.
View institutional ownership trends for Amneal Pharmaceuticals
.

Which institutional investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Spark Investment Management LLC, Bank of America Corp DE, Strs Ohio, New York State Common Retirement Fund, and CWM Advisors LLC.
View insider buying and selling activity for Amneal Pharmaceuticals
.

Which institutional investors are buying Amneal Pharmaceuticals stock?

AMRX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., LSV Asset Management, Vanguard Group Inc., Prudential Financial Inc., Smith Asset Management Group LP, Cubist Systematic Strategies LLC, Alberta Investment Management Corp, and UBS Group AG. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Jeffrey P George, John Kiely, Joseph Todisco, Paul Bisaro, Paul M Meister, Pradeep Bhadauria, and Ted C Nark.
View insider buying and selling activity for Amneal Pharmaceuticals
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.25.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $1.27 billion and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis. Amneal Pharmaceuticals employs 5,500 workers across the globe.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is www.amneal.com.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.